First bio-printed human heart ushers in new era of longevity

First bio-printed human heart ushers in new era of longevity

Summary:  It’s alive! Fusing bioengineering and medical science, scientists successfully bio-print a human heart, promising to extend the lives of millions.


In an unprecedented scientific breakthrough, 2025 sees researchers successfully bio-print a fully functional human heart, using advanced 3D bioprinting technology. Starting with high-resolution CT scans, scientists create an intricate digital model capturing every minute detail of the heart's complex structure. This model serves as the blueprint for a state-of-the-art 3D bioprinter, which meticulously layers human stem cells and biodegradable scaffold materials to construct the organ with remarkable precision. 

Once printed, the nascent heart is placed in a specialised bioreactor that mimics the physiological conditions of the human body. Here, the heart matures over several weeks, allowing the cells to organise and differentiate properly, establishing vital networks of blood vessels and electrical pathways necessary for normal heart function. In a groundbreaking surgical procedure, the matured human heart is then transplanted into a pig for testing. 

The implications of this achievement are monumental. It promises to alleviate the global shortage of donor organs by providing bio-printed hearts tailored to the DNA of individual patients, thus reducing the risk of rejection. This breakthrough paves the way for extending human longevity by replacing failing organs with custom-made, fully compatible ones. Additionally, it opens avenues for innovation in bio-printing other complex organs, revolutionising regenerative medicine and personalised healthcare. 

This massive advance in biotechnology history captures global attention. The fusion of bioengineering and medical science promises to improve and lengthen the lives of millions in years to come. 

Potential market impact: The success in bio-printed organs sees growth expectations jump for the biotechnology and 3D printing sectors. Most companies in this space are in the start-up phase, but watch for a rash of IPOs in the space. More generally, this surge in innovation and investment could reshape the healthcare industry, leading to improved patient outcomes and significant economic growth.


This content is marketing material and should not be regarded as investment advice. Trading financial instruments carries risks and historic performance is not a guarantee of future results.
The instrument(s) referenced in this content may be issued by a partner, from whom Saxo receives promotional fees, payment or retrocessions. While Saxo may receive compensation from these partnerships, all content is created with the aim of providing clients with valuable information and options.

This content is marketing material.

None of the information provided on this website constitutes an offer, solicitation, or endorsement to buy or sell any financial instrument, nor is it financial, investment, or trading advice. Saxo Bank Switzerland and its entities within the Saxo Bank Group provide execution-only services, with all trades and investments based on self-directed decisions. Analysis, research, and educational content is for informational purposes only and should not be considered advice nor a recommendation.

Saxo Bank Switzerland’s content may reflect the personal views of the author, which are subject to change without notice. Mentions of specific financial products are for illustrative purposes only and may serve to clarify financial literacy topics. Content classified as investment research is marketing material and does not meet legal requirements for independent research.

Saxo Bank Switzerland partners with companies that provide compensation for promotional activities conduced on its platform. Additionally, Saxo Bank Switzerland has agreements with certain partners who provide retrocession contingent upon clients purchasing specific products offered by these partners.

While Saxo Bank Switzerland receives compensation from these partnerships, all educational and research content remains focused on providing information to clients.  

Before making any investment decisions, you should assess your own financial situation, needs, and objectives, and consider seeking independent professional advice. Saxo Bank Switzerland does not guarantee the accuracy or completeness of any information provided and assumes no liability for any errors, omissions, losses, or damages resulting from the use of this information.

The content of this website represents marketing material and is not the result of financial analysis or research. It has therefore not been prepared in accordance with directives of the Swiss Bankers Association designed to promote the independence of financial research and is not subject to any prohibition on dealing ahead of the dissemination of the marketing material.

Saxo Bank (Schweiz) AG
The Circle 38
CH-8058
Zürich-Flughafen
Switzerland

Contact Saxo

Switzerland
Switzerland

All trading carries risk. Losses can exceed deposits on margin products. You should consider whether you understand how our products work and whether you can afford to take the high risk of losing your money. To help you understand the risks involved we have put together a general Risk Warning series of Key Information Documents (KIDs) highlighting the risks and rewards related to each product. The KIDs can be accessed within the trading platform. Please note that the full prospectus can be obtained free of charge from Saxo Bank (Switzerland) Ltd. or the issuer.

This website can be accessed worldwide however the information on the website is related to Saxo Bank (Switzerland) Ltd. All clients will directly engage with Saxo Bank (Switzerland) Ltd. and all client agreements will be entered into with Saxo Bank (Switzerland) Ltd. and thus governed by Swiss Law. 

The content of this website represents marketing material and has not been notified or submitted to any supervisory authority.

If you contact Saxo Bank (Switzerland) Ltd. or visit this website, you acknowledge and agree that any data that you transmit to Saxo Bank (Switzerland) Ltd., either through this website, by telephone or by any other means of communication (e.g. e-mail), may be collected or recorded and transferred to other Saxo Bank Group companies or third parties in Switzerland or abroad and may be stored or otherwise processed by them or Saxo Bank (Switzerland) Ltd. You release Saxo Bank (Switzerland) Ltd. from its obligations under Swiss banking and securities dealer secrecies and, to the extent permitted by law, data protection laws as well as other laws and obligations to protect privacy. Saxo Bank (Switzerland) Ltd. has implemented appropriate technical and organizational measures to protect data from unauthorized processing and disclosure and applies appropriate safeguards to guarantee adequate protection of such data.

Apple, iPad and iPhone are trademarks of Apple Inc., registered in the U.S. and other countries. App Store is a service mark of Apple Inc.